Screener
Recursion Pharmaceuticals, Inc. RXRX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Recursion Pharmaceuticals, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
FAQ
- What is Recursion Pharmaceuticals, Inc.'s EBITDA margin?
- Recursion Pharmaceuticals, Inc. (RXRX) reported EBITDA margin of -848.9% in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s EBITDA margin changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s EBITDA margin increased by 6.5% year-over-year, from -907.8% to -848.9%.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s EBITDA margin?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s EBITDA margin has grown at a -18.0% compound annual growth rate (CAGR), from -2,036.1% to -755.8%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Recursion Pharmaceuticals, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude